Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health News of Alabama.
Press releases published on June 18, 2025
Sienna Senior Living Completes Second Acquisition in Ottawa in 2025
GlobeNewswire
·
June 18, 2025
MARKHAM, Ontario, June 18, 2025 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. ("Sienna" or the "Company") (TSX: SIA) announced today that it has finalized its previously announced acquisition of Hazeldean Gardens Retirement Residence, a 172-suite …
IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025
GlobeNewswire
·
June 18, 2025
ASCO 2025 overall survival data bolster IMNN-001’s potential in advanced ovarian cancer, supported by robust translational results at ESMO Results from OVATION 2 Study reinforce IMNN-001 mechanism of action, producing IL-12 and key anti-cancer immune …
R1 Appoints Dave Wojczynski as President to Lead Physician Revenue Cycle Management Business
GlobeNewswire
·
June 18, 2025
MURRAY, Utah, June 18, 2025 (GLOBE NEWSWIRE) -- R1 (“R1” or the “Company”), an industry leader in managing and intelligently automating healthcare revenue management, today announced Dave Wojczynski, a seasoned healthcare executive with extensive …
Pacira BioSciences Debuts Inspiring New Film Highlighting One Patient’s Journey to Pain Relief and Innovation in Care at BIO 2025
GlobeNewswire
·
June 18, 2025
- Produced for Pacira by BBC StoryWorks Commercial Productions, The Next Frontier: Mark …
Aligos Therapeutics Appoints Kieron Wesson as Vice President, Head of Chemistry Manufacturing Controls (CMC)
GlobeNewswire
·
June 18, 2025
SOUTH SAN FRANCISCO, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today …
Synergy CHC (NASDAQ: SNYR) Expands FOCUSfactor® to UAE & Turkey — Ignites Global Growth and New Revenue Streams
GlobeNewswire
·
June 18, 2025
WESTBROOK, Maine, June 18, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a fast-growing consumer health and wellness company, announced today that it has expanded its international licensing deal with Gravity …
PharmaTher Applauds FDA's New Commissioner’s National Priority Voucher (CNPV) Program, Citing Potential to Accelerate its Ketamine Programs for Mental Health, Pain, and Neurological Disorders, and National Security Applications
GlobeNewswire
·
June 18, 2025
TORONTO, June 18, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) ("PharmaTher" or the "Company"), a company focused on unlocking the pharmaceutical potential of ketamine, today announced its strong support for the U.S. Food …
Neurona Doses First Patient in Phase 1/2 Trial of NRTX-1001 Cell Therapy in Adults with Drug-Resistant, Bilateral Mesial Temporal Lobe Epilepsy (MTLE)
GlobeNewswire
·
June 18, 2025
- First patient received bilateral administration of NRTX-1001; no significant surgical complications or adverse events reported to date - - Trial funded by a $14 million grant from California Institute for Regenerative Medicine - - Data from this …
Route 92 Medical Appoints Medtech Industry Veterans Mitch Hill and Lucas Buchanan to its Board of Directors
GlobeNewswire
·
June 18, 2025
SAN MATEO, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced the election of Mitch Hill and …
Bionano Recaps Global Momentum Behind Optical Genome Mapping at the 2025 Annual Meeting of the European Society of Human Genetics Held Recently in Milan, Italy
GlobeNewswire
·
June 18, 2025
SAN DIEGO, June 18, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics (NASDAQ: BNGO) recently participated in the European Society of Human Genetics (ESHG) conference held in Milan, Italy, from May 24-27, 2025. The event highlighted the use of optical genome …
Prenetics Divests ACT Genomics to Delta Electronics as Part of up to US$71.78 Million Transaction
GlobeNewswire
·
June 18, 2025
Bolsters Prenetics’ pro-forma cash reserves to approximately US$86 million, and pro-forma cash and short-term assets to approximately US$117 million Prenetics simplifies investment thesis as company focuses on high-growth consumer health brands IM8, …
Moleculin Participates in Virtual Investor “What This Means” Segment
GlobeNewswire
·
June 18, 2025
Watch the “What This Means" segment here HOUSTON, June 18, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to- …
Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
GlobeNewswire
·
June 18, 2025
Global Phase 3 BRAVE study will evaluate the efficacy and safety of omaveloxolone in children 2 to <16 years old with Friedreich ataxia, a rare neurodegenerative disorder BRAVE study will explore the potential of omaveloxolone to address the critical unmet …
XOMA Royalty Declares Quarterly Preferred Stock Dividends
GlobeNewswire
·
June 18, 2025
EMERYVILLE, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty’s Series A and Series B Cumulative Preferred Stock: …
Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML
GlobeNewswire
·
June 18, 2025
Annamycin aims to eliminate cardiotoxicity associated with anthracyclines used to treat about 60% of all children with cancer FDA recommends inclusion of patients as young as 6 months – younger than Moleculin had proposed – to be allowed in the pediatric …
Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors
GlobeNewswire
·
June 18, 2025
New intellectual property builds on Palvella’s multi-layered exclusivity strategy Patent term expected through at least 2038 WAYNE, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage …
F2G Announces Publication in The Lancet Infectious Diseases of Phase 2b Data Demonstrating Positive Therapeutic Responses in Patients with Serious Invasive Fungal Diseases Treated with Oral Olorofim
GlobeNewswire
·
June 18, 2025
MANCHESTER, United Kingdom, June 18, 2025 (GLOBE NEWSWIRE) -- F2G Ltd, a clinical-stage biopharmaceutical company developing olorofim, a novel therapy to treat life-threatening rare fungal infections with high unmet medical need, today announced the …
Gradient Denervation Technologies Announces Acceptance into FDA’s Total Product Life Cycle Advisory Program for Development of its Pulmonary Artery Denervation System
GlobeNewswire
·
June 18, 2025
PARIS, June 18, 2025 (GLOBE NEWSWIRE) -- Gradient Denervation Technologies announced today that it has been accepted into the Total Product Life Cycle Advisory Program (TAP) Pilot from the U.S. Food and Drug Administration (FDA) for the development of its …
Gradient Denervation Technologies annonce son admission au programme consultatif de la FDA sur le cycle de vie complet des produits pour le développement de son système de dénervation de l’artère pulmonaire
GlobeNewswire
·
June 18, 2025
PARIS, 18 juin 2025 (GLOBE NEWSWIRE) -- Gradient Denervation Technologies annonce ce jour son admission au programme pilote TAP (Total Product Life Cycle Advisory Program, programme consultatif sur le cycle de vie complet des produits) de la Food and Drug …
Eccogene Announces First Patient Dosed in Phase 1b Trial of AZD5004/ECC5004, a Novel Oral GLP-1 Receptor Agonist, in China
GlobeNewswire
·
June 18, 2025
BOSTON and SHANGHAI, June 18, 2025 (GLOBE NEWSWIRE) -- Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic and inflammatory conditions, today announced that the first …